195 related articles for article (PubMed ID: 30429026)
1. Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.
Saito T; Tsuta K; Ishida M; Ryota H; Takeyasu Y; Fukumoto KJ; Matsui H; Taniguchi Y; Yanagimoto H; Kurata T; Murakawa T
Lung Cancer; 2018 Nov; 125():230-237. PubMed ID: 30429026
[TBL] [Abstract][Full Text] [Related]
2. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
Shigeta N; Murakami S; Yokose T; Isaka T; Shinada K; Nagashima T; Adachi H; Shigefuku S; Murakami K; Miura J; Kikunishi N; Watabe K; Saito H; Ito H
Thorac Cancer; 2024 Jun; 15(17):1343-1349. PubMed ID: 38698758
[TBL] [Abstract][Full Text] [Related]
3. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
4. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
[TBL] [Abstract][Full Text] [Related]
5. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
7. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN
Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383
[TBL] [Abstract][Full Text] [Related]
8. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Skov BG
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
[TBL] [Abstract][Full Text] [Related]
10. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
[TBL] [Abstract][Full Text] [Related]
11. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
[TBL] [Abstract][Full Text] [Related]
13. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564
[TBL] [Abstract][Full Text] [Related]
15. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
[TBL] [Abstract][Full Text] [Related]
16. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
[TBL] [Abstract][Full Text] [Related]
17. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
[TBL] [Abstract][Full Text] [Related]
18. Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.
Chan AWH; Tong JHM; Kwan JSH; Chow C; Chung LY; Chau SL; Lung RWM; Ng CSH; Wan IYP; Mok TSK; To KF
Mod Pathol; 2018 Sep; 31(9):1381-1390. PubMed ID: 29713040
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.
Grote HJ; Feng Z; Schlichting M; Helwig C; Ruisi M; Jin H; Scheuenpflug J; Gann CN; Su Z; Reck M; Vokes EE; Kerr KM
J Thorac Oncol; 2020 Aug; 15(8):1306-1316. PubMed ID: 32353599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]